System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Steeve DemoProfile is an expert in Oncology at Baylor Scott & White Health (United States). As of April 2023, ScienceLeadR ranks Steeve DemoProfile in the top 1% of experts worldwide for Sarcoma, Chondrosarcoma and Synovitis. Steeve DemoProfile has authored 920 publications, the most recent in 2023, and is an investigator in 103 clinical trials, 6 of them ongoing. SLR score: 6,992 (community average: 125). How the SLR is computed.

LeadR Profile

Steeve DemoProfile Baylor Scott & White Health United States
6 992 ScienceLeadR Reputation 6992

Unlock

Register Login
Network Map

Oncology

Subspecialties: Public Health - Therapeutics - Surgery

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1995 - 2023
Source: PubMed

Mayo Clinic

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 920

Citations

Citations: 24 536 1st author: 90 Last author: 172 Unique author: 33

Main journals

Ann Oncol 100
Eur J Cancer 81
Bull Cancer 72
J Clin Oncol 39
Lancet Oncol 33

Best Journals

Lancet Oncol 33
Ann Oncol 18
Lancet 5

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Efficacy and Safety of Adjuvant Radiotherapy in Re-excised Soft-tissue Sarcoma After Unplanned Resection.
PMID 36971503 — sarcoma, neoplasms, safety, multivariate analysis, tissues, radiotherapy, adjuvant		Oncologist20235
Radioligand therapies in cancer: mapping the educational landscape in Europe.
PMID 37058168 — education, teaching, nuclear medicine, universities, therapeutics, neoplasms		Eur J Nucl Med Mol Imaging20234
Why will there never be a randomized trial for NTRK-rearranged tumors?
PMID 37068657 — neoplasms		Ann Oncol Top journal20238
[Endometrial stromal sarcoma: French Guidelines from the French Sarcoma Group and the Rare Malignant Gynecologic Tumors Group].
PMID 36990895 — neoplasms, morcellation, sarcoma, sarcoma, endometrial stromal, therapeutics		Bull Cancer20231
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial.
PMID 37059834 — glioma, safety, molecular biology, neoplasms, thyroid carcinoma, anaplastic, therapeutics		Nat Med Top journal2023160

Clinical Studies 103

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 31 Study Chair: 3 Sub-Investigator: 3

By phase:

Phase 2 47
Phase 3 23
N/A 16
Phase 1 10
Phase 1/Phase 2 5
Phase 2/Phase 3 1

By status:

Completed 54
Recruiting 31
Active, not recruiting 11
Terminated 3
Unknown status 2
Suspended 1

By type:

By Monocentric/Multicentric:

monocentric 14
multicentric2to4 7
multicentric5to9 18
multicentricup10 63

Main Topics

Ongoing Clinical Trials

6 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
HDM201 and Pazopanib in Patients With P53 Wild type Advanced Metastatic Soft Tissue Sarcomas
NCT05180695 — safety, pharmaceutical preparations, disease progression, sarcoma, genes, p53, response evaluation criteria in solid tumors, tissues		Phase 1/Phase 2Active not recruiting2022
Study of Vimseltinib for Tenosynovial Giant Cell Tumor
NCT05059262 — cells, genes, dcc, safety, giant cell tumors, giant cell tumor of tendon sheath, neoplasms, double-blind method, tendons, giant cells, synovitis, pigmented villonodular, therapeutics, synovitis		Phase 3Active not recruiting2021
Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist Ten)
NCT05009927 — mesylates, gastrointestinal stromal tumors, neoplasms, tablets, maintenance, protein-tyrosine kinases, tyrosine, therapeutics, imatinib mesylate, mutation		Phase 2Recruiting2022
Study of INBRX 109 in Conventional Chondrosarcoma
NCT04950075 — cells, chondrosarcoma, apoptosis, cell death		Phase 2Active not recruiting2021
Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING)
NCT04921553 — registries, genes, quality of life, data collection, proto-oncogene proteins c-sis, neoplasms, gene rearrangement, gene fusion, therapeutics, mutation		N/ARecruiting2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS